Global Janus Kinase (JAK) Inhibitors Market 2019-2023

Global Janus Kinase (JAK) Inhibitors Market 2019-2023

  • July 2019 •
  • 133 pages •
  • Report ID: 5804140 •
  • Format: PDF
Global Janus Kinase (JAK) Inhibitors Market: About this market

Global janus kinase (JAK) inhibitors are drugs that inhibit the abnormal functionality of enzymes in the JAK family such as JAK1, JAK2, JAK3, and TYK2. The inhibition of these enzymes helps interfere with the JAK-STAT signaling pathway, which has been found to play a key role in the development of various autoimmune disorders and cancer indications. This janus kinase (JAK) inhibitors market analysis considers sales from both autoimmune disorder and oncology. Our analysis also considers the sales of janus kinase (JAK) inhibitors in Asia, Europe, North America, ROW. In 2018, the autoimmune disorders segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high proven efficiency of these drugs will play a significant role in the autoimmune disorders segment to maintain its market position. Also, our global janus kinase (JAK) inhibitors market report also looks at factors such as increasing number of awareness campaigns, application in severe chronic indications, support from the growing healthcare insurance industry. However, the availability of alternative therapies, differential drug pricing, strong adverse effects may hamper the growth of the janus kinase (JAK) inhibitors industry over the forecast period.

Global Janus Kinase (JAK) Inhibitors Market: Overview

Application in severe chronic indications

The global JAK inhibitors market is expected to benefit significantly from the rising use of JAK inhibitors to treat various chronic diseases. The high efficacy of JAK inhibitors for the treatment of autoimmune disorders has increased their adoption for the treatment of rheumatoid arthritis, psoriatic arthritis. and ulcerative colitis. Research on the use of JAK inhibitors has shown significant results in the clinical stages, which has created the market potential for the vendors. Similarly, the unmet need for the treatment of graft-versus-host disease (GVHD) is high as the treatment landscape is dominated by off-label of therapies such as TNF inhibitors and interleukin inhibitors. To address the high unmet need, vendors in the global JAK inhibitors market are developing novel drugs to treat GVHD. Such factors will lead to the expansion of the global janus kinase (JAK) inhibitors market at a CAGR of over 18% during the forecast period.

Special drug designations

One of the major benefits that most JAK inhibitors have is the special drug designations given by regulatory bodies. Many drugs have received designations such as the orphan drug designation from regulatory bodies such as the US FDA and the EMA. The orphan drug designation is given to a drug by the FDA when it is being developed to treat an indication that less than 200.000 people have in the US. Vendors that have received the orphan drug designation for their drug will get certain benefits associated with regulations and taxes. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global janus kinase (JAK) inhibitors market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading janus kinase (JAK) inhibitors manufacturers, that include Astellas Pharma Inc., Eli Lilly and Co., Incyte Corp., Novartis AG, and Pfizer Inc.

Also, the janus kinase (JAK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.